Understanding how HER2 mutations affect treatment responses in lung cancer
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
This study is looking at how different changes in the HER2 gene affect how well people with non-small cell lung cancer respond to specific treatments, so we can find the best options for each type of mutation and understand why some tumors stop responding to these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11130408 on NIH RePORTER |
What this research studies
This research investigates the structural differences in HER2 mutations that affect how patients with non-small cell lung cancer (NSCLC) respond to targeted therapies. By analyzing over 80 different mutations, the study aims to identify which specific HER2 inhibitors are most effective for each mutation type. The research also explores how tumors develop resistance to these treatments, which can occur through additional mutations or other mechanisms. This comprehensive approach seeks to improve treatment selection for patients with HER2-mutant cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-mutant non-small cell lung cancer.
Not a fit: Patients without HER2 mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with HER2-mutant lung cancer.
How similar studies have performed: While there has been some success in targeting HER2 in other cancers, this specific approach for HER2-mutant NSCLC is relatively novel and untested.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Heymach, John V. — University of Tx Md Anderson Can Ctr
- Study coordinator: Heymach, John V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.